FDA Approves LEQEMBI IQLIK Subcutaneous Injection for Early Alzheimer’s Maintenance Therapy
Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for LEQEMBI IQLIK (lecanemab-irmb)…
Read More...
Read More...
